Organon (OGN) Long-Term Deferred Tax (2020 - 2026)
Organon (OGN) recorded quarterly Long-Term Deferred Tax of $1.5 billion in Q1 2026, little changed quarter-over-quarter from $1.5 billion in Q4 2025, and up 2.82% on a YoY basis from $1.5 billion in Q1 2025.
Organon (OGN) Long-Term Deferred Tax (2020 - 2026) Analysis & Trends
Organon's Long-Term Deferred Tax history runs 7 years deep, the most recent figure standing at $1.5 billion for Q1 2026.
- In Q1 2026, Long-Term Deferred Tax rose 2.82% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 2.82% YoY), while the FY2025 annual figure was $1.5 billion, up 3.22% from the prior year.
- Long-Term Deferred Tax was $1.5 billion for Q1 2026 at Organon, roughly flat from $1.5 billion in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $1.6 billion in Q2 2025 to a low of $640.0 million in Q1 2022.
- Historically, Long-Term Deferred Tax has averaged $1.1 billion across 5 years, with a median of $1.2 billion in 2024.
- The sharpest annual moves came in 2022 and 2024: Long-Term Deferred Tax fell 11.55% in 2022, then jumped 103.13% in 2024.
- A 5-year view of Long-Term Deferred Tax shows it stood at $754.0 million in 2022, then jumped by 63.26% to $1.2 billion in 2023, then advanced by 21.12% to $1.5 billion in 2024, then increased by 3.22% to $1.5 billion in 2025, then dropped by 0.39% to $1.5 billion in 2026.
- The last three Long-Term Deferred Tax figures came in at $1.5 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.53 Bn |
| Dec 31, 2025 | 1.54 Bn |
| Sep 30, 2025 | 1.54 Bn |
| Jun 30, 2025 | 1.57 Bn |
| Mar 31, 2025 | 1.49 Bn |
| Dec 31, 2024 | 1.49 Bn |
| Sep 30, 2024 | 1.43 Bn |
| Jun 30, 2024 | 1.20 Bn |
| Mar 31, 2024 | 1.19 Bn |
| Dec 31, 2023 | 1.23 Bn |
| Sep 30, 2023 | 702.00 Mn |
| Jun 30, 2023 | 716.00 Mn |
| Mar 31, 2023 | 704.00 Mn |
| Dec 31, 2022 | 754.00 Mn |
| Sep 30, 2022 | 666.00 Mn |
| Jun 30, 2022 | 647.00 Mn |
| Mar 31, 2022 | 640.00 Mn |
| Dec 31, 2021 | 694.00 Mn |
| Sep 30, 2021 | 753.00 Mn |
| Jun 30, 2021 | 707.00 Mn |